MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today its financial results for the year ended December 31, 2006. The Company reported total revenues of $376 million for the year ended December 31, 2006, an increase of $202 million (or 116%) compared to revenues of $174 million for the same period last year. The increase was primarily due to the growth in revenues arising from worldwide Tarceva® (erlotinib) sales, and the addition of Macugen® (pegaptanib sodium injection)-related revenue streams. Total worldwide net sales of Tarceva for 2006 were $650 million, as reported by Genentech, Inc. and Roche, the Company’s collaborators for Tarceva, and represent 109% growth in global sales compared to 2005 global sales of $311 million.
